Government, Policy & Advocacy

The American Academy of Child and Adolescent Psychiatry is a U.S.-based professional medical association for child and adolescent psychiatrists, with national coverage across the United States. Its mission is to promote the healthy development of children, adolescents, and families through advocacy, education, and research, while also meeting the professional needs of its physician members. AACAP also maintains public-facing resources for families, youth, and clinicians, including psychiatric education materials and a psychiatrist finder. AACAP is not a psychedelic-specific advocacy group, but it is adjacent to psychedelic medicine through its research, education, and policy work on child and adolescent mental health, substance use, and psychopharmacology. Its website and publications show active interest in evidence-based treatment, youth substance use education, and psychopharmacology research, and its research reporting has referenced psychedelic medications such as psilocybin in the context of pediatric depression research. AACAP’s role in the field is primarily as a professional standards-setter and source of clinical guidance rather than a campaign organization for psychedelic access.

The American Psychiatric Association is the national medical specialty society for psychiatry in the United States, with headquarters in Washington, DC and a membership base of psychiatric physicians. It serves psychiatrists and the broader mental health field through official position statements, clinical guidance, journals, and public policy communications. Its core activity is to represent psychiatry in clinical, professional, and policy discussions affecting mental health care. APA has an explicit, cautious stance on psychedelics and empathogens in mental health care. Its 2022 position statement says there is not yet adequate scientific evidence to endorse use outside approved investigational studies, while supporting continued research under strong scientific and regulatory standards. In 2024 APA also submitted comments to FDA on MDMA and in 2026 it publicly welcomed federal investment in psychedelic research while reiterating the need for controlled studies and patient protections.

APSTA, the Association for Psychedelic Science and Therapy Austria, is based in Vienna and describes itself as Austria's leading network for experts in psychedelic research and therapy. It serves medical, psychotherapeutic, psychological, and other professional audiences, with a stated focus on connecting professionals and sharing knowledge, best practices, and experience. Its core activities center on networking, setting guidelines and standards, and education and outreach. APSTA presents itself as a professional association focused on safe, responsible, and evidence-based use of psychedelic substances in therapy and research. Its role appears primarily educational and field-building rather than legislative, with emphasis on ethical practice, public information, and interdisciplinary exchange. Documented examples on its site include supporting research projects, promoting standards for therapy and research, and informing the public about opportunities and risks of psychedelic therapies.

Autistic Psychedelic Community (APC) is a U.S.-based, autistic-led community and educational project founded in March 2020. Its website describes it as a neurodivergent-led space for people exploring autism, psychedelics, altered states, healing, identity, and lived experience. APC says it operates as a global community with a Los Angeles home node and offers online peer support and community connection. APC frames its role as building shared language, community support, and safer exploration for neurodivergent people, including autistic people and people with ADHD, who are navigating psychedelics. The organization says it is not a medical, psychological, or clinical service, but it does provide educational material, peer support, integration-oriented resources, and a sensory checklist for harm reduction. It also states that it aims to translate peer support and lived experience into frameworks that can inform clinical and academic work, which makes it relevant to researchers, clinicians, and neurodiversity-affirming psychedelic practice.

Pharmaceutical company responsible for LUMRYZ REMS implementation in the U.S., including prescriber and pharmacy certification and controlled distribution safeguards.

The Beckley Foundation is a UK-based non-profit founded in 1998 and based in Oxford, with a global remit focused on psychedelic research and drug policy reform. It works through scientific and policy programmes and collaborates with researchers, political leaders, and institutions internationally. Its website describes its purpose as investigating psychoactive substances and developing evidence-based drug policies grounded in health, harm reduction, cost-effectiveness, and human rights. In psychedelic medicine and drug policy, the Beckley Foundation functions as a research and reform organization rather than a patient service group. Current documented work includes the Beckley/Imperial research programme, new collaboration with King’s College London on LSD and mystical experience research, and policy outputs such as Roadmaps to Regulation: MDMA, which argues for decriminalization and a strictly regulated legal market. This makes it relevant for researchers, clinicians, funders, and policy groups interested in clinical evidence, regulatory models, and translating psychedelic science into access and reform discussions.

Biopharmaceutical company responsible for BRIXADI REMS implementation in the U.S., with certified provider and pharmacy requirements and controlled outpatient distribution pathways.

BrainFutures is a national US nonprofit based in Baltimore, Maryland, that bridges research, innovation, and practice to advance evidence-based brain interventions. It serves policymakers, providers, funders, and the public by producing evidence-based issue briefs, recommendations, educational resources, and stakeholder convenings focused on brain health and recovery outcomes. In psychedelic medicine, BrainFutures is explicit and active: it launched a psychedelic-assisted therapy initiative in 2021 to support policy-oriented research, coalition building, and education for policymakers, healthcare providers, payers, and the public. Its current work includes professional practice guidelines, psychedelic access pathway research, coding and reimbursement guidance, parity-focused access work, and a survey on psychedelic therapy curricula in academia. It positions itself as a bridge to equitable, system-ready access and a convenor for multi-stakeholder collaboration on regulation, training, reimbursement, and implementation.

Canadian public HTA and reimbursement review body supporting evidence appraisal for access decisions.

Canada�s federal health research funding agency setting national biomedical and health-services research priorities.

The Center for Psychedelic Policy is a U.S.-focused policy think tank that works on psychedelic care affordability and state-level implementation. Its official materials say it aims to equip states with policies, funding models, and strategies for affordable psychedelic care, and it serves legislators, state agencies, funders, advocates, and other stakeholders working on regulated access. CPP’s current field role is centered on legislative analysis, implementation guidance, and public education about state-funded or state-regulated access pathways. Its publicly listed projects include the National Psychedelic Landscape Assessment, which tracks state bills and policy trends, and Ground Game, a podcast that translates research and policy developments for legislators, funders, and advocates. The organization also highlights Oregon as a key reference point and points to lessons from Oregon and Colorado for program design and oversight.

U.S. national public health agency responsible for surveillance, risk communication, and epidemiologic guidance.

The Centre for Evidence Based Drug Policy is a UK-based evidence and policy forum that promotes informed debate on drug policy reform. It describes itself as non-governmental, politically unaffiliated, and working on a cross-party basis to influence Parliamentarians and other decision makers. Its stated focus includes drug policy governance, medical psychedelics, and cannabis and CBD, with an emphasis on reducing harm, improving public health, and unlocking medical and economic benefits. The organization plays a drug policy reform and public policy role rather than a direct patient-service role. It explicitly campaigns for evidence-based reform across areas such as cannabis and psychedelics-based medicines, heroin-assisted treatment, and naloxone access, and it has a visible medical psychedelics workstream centered on psilocybin rescheduling and patient access. Documented current activities include a CBD regulatory campaign, a request for clarification on the UK Food Standards Agency's CBD acceptable daily intake update, and policy briefings to government, opposition, and international decision makers.

Cepda, or Center for Psykedelisk Dannelse, is a Danish nonprofit based in Denmark that presents itself as a community, education, and support organization working to build a more responsible, evidence-informed approach to psychedelics. Its website says it builds bridges between research, practitioners, users, and decision-makers, and it operates public-facing educational content, an online community, and in-person or online sharing circles. In the psychedelic field, Cepda is primarily a public education and advocacy-oriented stakeholder rather than a clinical provider. It publishes explainer content on psychedelic therapy, microdosing, tripsitting, and integration, maintains a free project database of Danish student research, and highlights collaboration with Danish and international research actors through its research page. The organization also frames its work around social integration of psychedelics and community support, which suggests practical alignment with researchers, clinicians, funders, policy groups, and patient or user communities seeking education, safe-use resources, and field-building partnerships.

Chacruna is a nonprofit psychedelic education and advocacy platform based in the United States with global reach through online publishing, courses, conferences, and multilingual programming. Its work centers on psychedelic plant medicines, ethics, cultural justice, reciprocity, and Indigenous knowledge, with content and activities aimed at researchers, clinicians, educators, policy audiences, and the broader public. The organization says it bridges ceremony and science and makes academic knowledge more accessible through public-facing education. Chacruna plays an explicit role in psychedelic justice and policy-adjacent advocacy by foregrounding cultural context, equity, and protection of sacred plants and traditions. Current documented initiatives include the Indigenous Reciprocity Initiative of the Americas, which supports community-led Indigenous projects, the Psychedelic Culture conference, the bilingual Chacruna Latinoamérica platform, and courses on diversity, culture, social justice, ceremony, ethics, and reciprocity. These activities make it a potential partner for researchers, clinicians, funders, and policy groups seeking cultural consultation, educational programming, and community-centered collaboration.

The Chief Scientist Office (CSO) of the Scottish Government funds NHS and health research across Scotland, and has supported University of Edinburgh evaluability work on ketamine-assisted therapy and the development of the Scottish Psychedelic Research Group to build Scotland’s capacity for psychedelic-assisted therapy studies.

Clusterbusters is a long-running U.S. disease-community organization for people living with cluster headache and their families. It combines patient support, treatment education, research support, and advocacy around access to effective therapies, including psychedelic options such as psilocybin and LSD. For Blossom, Clusterbusters fills an important gap because it is one of the clearest headache-focused patient stakeholders with explicit psychedelic relevance. Its public work links patient registry infrastructure, annual conferences, and advocacy around both conventional access issues like oxygen and psychedelic research and treatment pathways.

Coalition for Better Community Health is a Washington state coalition focused on supervised psilocybin access and psychedelic care policy. Its public materials describe a Washington-based campaign that works with veterans, first responders, therapists, counselors, psychological associations, and other community stakeholders. The organization presents itself as a 501(c)(4) and frames its work around safe psychedelic care and medical-first access pathways. The coalition’s role is primarily policy advocacy and coalition-building for psilocybin legislation in Washington State, with a stated emphasis on regulated, supervised use rather than recreational access. Its site says its 2025 legislative effort included HB 1433 and SB 5201, and that the bill was stalled until the 2026 session while it continued organizing supporters. Source materials also reference a Washington Department of Health supervised-access approach and a psilocybin pilot program concept, indicating an active legislative campaign and policy education function.

Colorado Division of Professions and Occupations program overseeing facilitator licensing, renewals, complaints, and rule/policy resources for natural medicine services.

Colorado Department of Revenue division responsible for licensing and regulating natural medicine businesses, including healing centers, cultivations, product manufacturers, and testing facilities.

The Colorado Natural Medicine Advisory Board is a statutorily created state board within Colorado’s Division of Professions and Occupations that advises the state licensing authority on implementing Colorado’s natural medicine regulatory program. It operates in Colorado and serves statewide public interests, with board membership drawn to reflect expertise in natural medicine, research, cultivation, public health, insurance, behavioral health, veterans, Indigenous use, and criminal justice reform. Its core work is to make recommendations on rules, public education, training, facilitator qualifications, data collection, and access considerations. In Colorado’s regulated natural medicine system, the board functions as an implementation and oversight working group rather than a direct service provider or advocacy nonprofit. Documented current activity includes recommending state action on ibogaine sourcing and cultural protocols, including alignment with the Nagoya Protocol and a federal Controlled Substances Act waiver request for import pathways. Its role in the field is to shape how regulated access is designed, safer use information is communicated, and whether additional natural medicines or insurance coverage considerations should be evaluated over time.

The Congressional Psychedelics Advancing Therapies (PATH) Caucus is a bipartisan U.S. congressional caucus centered in federal policymaking and legislative advocacy. It operates nationally in Congress and is co-chaired by Representatives Lou Correa and Jack Bergman, with a stated focus on evidence-based psychedelic science, clinical research, and federal pathways for lawful therapeutic use. Its public-facing work is especially tied to veterans and the Department of Veterans Affairs. In psychedelic medicine, the caucus frames its role as promoting rigorous clinical research and increasing awareness among lawmakers and the media about FDA-approved psychedelic trials, rather than legalization or recreational use. Documented current efforts include meetings with VA leadership, support for VA research and access planning, a 2025 bill to create Veterans-focused centers of excellence, and earlier amendments and requests aimed at expanding federal study of psychedelic-assisted therapies for PTSD, depression, and substance use disorder. Practical collaboration opportunities are strongest for researchers, clinicians, funders, policy groups, and veteran-serving communities working on study design, implementation, access planning, and evidence translation.

U.S. federally directed defense-health research program office administering targeted grants, including mental-health priorities.

Brazil's National Council for Scientific and Technological Development (CNPq) is the country's primary public funding agency for scientific research, providing grants, scholarships, and R&D support to universities and research institutions nationwide. CNPq ranks among the top global funders of psychedelic science, having supported seminal ayahuasca clinical trials, pharmacological studies, and productivity fellowships for researchers who established Brazil as a world leader in psychedelic psychiatry.

CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior) is Brazil's federal agency for graduate education improvement, providing scholarships, postdoctoral fellowships, and institutional research grants to universities nationwide. Ranked among the top-six global funders of psychedelic research in a 2023 Scopus analysis, CAPES has financed ayahuasca neuroscience studies, clinical investigations, and postdoctoral programmes that underpin Brazil's internationally recognised psychedelic research ecosystem.

The Czech Health Research Council (AZV ČR) is an organisational component of the Czech Ministry of Health responsible for funding applied health research, distributing over 1 billion CZK annually across approximately 90 supported projects per year. It provided the primary grant for the PSIKET001 trial — a landmark double-blind comparison of psilocybin versus ketamine for treatment-resistant depression at the National Institute of Mental Health — with a total budget of 12 million CZK.

Czech Psychedelic Society (CZEPS) is a Czech nonprofit association based in Czechia that creates a public forum for discussion of psychedelic substances, their risks and benefits, and related policy. Its work is national in scope and centers on public education, connecting professionals with the public, and mediating access to current information. The organization also states that it aims to reduce harms connected to illicit use and the black market. CZEPS has an explicit role in psychedelic policy and drug policy reform, including legislative and public policy activity. Its legislative working group provides legal and public policy expertise, tracks foreign regulatory models, publishes analyses and popular educational materials, and promotes an evidence-based approach to psychoactive substances. Documented current initiatives include its Czech-language translation and summary work around How to Regulate Psychedelics and its engagement with broader European and Czech policy discussions, including PsychedeliCare-related outreach.

Decriminalize Nature is a U.S.-based grassroots network that works through national support and local chapters in cities, states, and some international locations listed on its site, including chapters in places such as California, Michigan, Minnesota, France, and Canada. Its core activities include community organizing, public education, local campaign building, and encouraging local governments to change policy around entheogenic plants and fungi. The organization says its local chapters are the primary vehicle for change and that chapters build awareness, educate the public, and propose legislation. In psychedelic policy, Decriminalize Nature focuses on decriminalization and expanded access for entheogenic plants and fungi, with a stated emphasis on direct political action and local change rather than expensive ballot-driven approaches. Its site describes a five-point plan aimed at incorporating reverence, social equity, and community-serving markets into policy discussions, and its organizer materials support local campaigns and legislation efforts. Potential collaboration areas include local policy work, public education, research-informed advocacy, and coalition building with clinicians, funders, patient communities, and reform groups that want to support access-focused civic campaigns.

Drug Policy Alliance is a U.S.-based nonprofit policy advocacy organization headquartered in New York City, with state offices in California, New York, and Washington, D.C. It works nationally on drug policy reform through policy solutions, organizing, public education, and advocacy focused on evidence, health, equity, and human rights. Its public-facing work centers on ending punitive drug policy and replacing it with regulated, health-oriented approaches. In psychedelics, DPA is an adjacent drug-policy stakeholder rather than a psychedelic-only organization. It has published documented educational material on psilocybin that frames psychedelics as promising therapeutic tools, discusses harm reduction, and notes the current federal illegality of psilocybin in most cases. Current campaigns also include decriminalization, marijuana criminalization reform, and broader public-health approaches to drug regulation, which makes DPA a relevant collaborator for researchers, clinicians, funders, and patient communities working on access, evidence translation, and equitable policy change.

Drug Science is a UK-based independent, science-led drugs charity founded in 2010 and headquartered in London, with work aimed at the UK public and international audiences. It focuses on building an evidence base for drug harms and benefits, and on equipping the public, media, and policymakers with scientific information to support sensible drug laws and evidence-based debate. In psychedelics, Drug Science is an explicit field actor rather than a peripheral observer. Its Medical Psychedelics Working Group promotes evidence-based psychedelic research and access, including support for removing psychedelic drugs from Schedule 1 restrictions, improving regulatory pathways for medical use, and producing educational resources for healthcare professionals and the public. The organization also publishes commentary and research-led content on psychedelic policy, clinical development, and public attitudes, and has recent documented activity around psilocybin regulation, psychedelic terminology, and UK research ecosystem updates.

End Wise is an Australian not-for-profit focused on access to psychedelic-assisted therapy in palliative and end-of-life care. Its mission is tightly scoped to people experiencing existential distress associated with terminal illness and to the clinicians and advocates working with them. This is a strong addition because it represents a patient-access niche that is often missing from psychedelic maps: end-of-life advocacy tied to a specific regulatory campaign. Its current work centers on the TGA scheduling process for psilocybin in palliative care, public submissions, and coalition-building.

The European Association for Palliative Care is a European professional association based in Milan, Italy, with members and collective member associations across Europe. Its stated purpose is to promote palliative care in Europe and to support people working in or interested in palliative care at scientific, clinical, and social levels. Its core activities include education, research, publications, and convening multidisciplinary professionals, patients, and volunteers in the field. EAPC is adjacent to psychedelic medicine through its palliative care role and participation in PsyPal, an EU-funded psilocybin trial focused on psychological distress in palliative patients with COPD, atypical Parkinsonian disorders, ALS, and multiple sclerosis. Public sources describe EAPC as a consortium partner in a broader European effort to build evidence for psychedelic therapy in palliative care and to support future ethical, cost-effective implementation. This makes EAPC relevant to researchers, clinicians, funders, and policy groups working on evidence generation, clinical integration, and patient-centered access in serious illness care.

EFNA, the European Federation of Neurological Associations, is a Brussels-based NGO that brings together 21 pan-European neurology patient groups and supports national and disease-specific patient organizations across Europe. Its core work is patient advocacy, awareness-raising, and capacity-building for people living with neurological disorders and their carers. EFNA also works with policymakers, researchers, clinicians, and other stakeholders to improve recognition of neurological disease burden and access to care and support. EFNA is not a psychedelic-specific organization, but it has an explicit adjacent role in the PsyPal consortium, where it is a patient advocacy partner in a European psilocybin trial for psychological distress in palliative care. EFNA also convenes policy platforms such as the MEP Interest Group on Brain Health and Neurological Conditions and has recent work on rare neurological conditions, mental health, equity of access, and patient involvement in research. For collaboration, EFNA is well positioned to connect researchers, clinicians, funders, and policy groups with neurology patient communities and to support patient-facing consultation, advocacy, and dissemination.

EU public health agency focused on disease surveillance, risk assessment, and evidence dissemination for member states.

EU medicines regulator for scientific review and pharmacovigilance, including psychiatric products with psychedelic relevance.

EU public drugs observatory and surveillance body publishing trend and risk evidence including hallucinogen/psychedelic monitoring.

Germany’s highest joint self-governing HTA decision body for coverage and evidence appraisal, including esketamine/Spravato dossiers.

Fundación inawe is a Spain-based nonprofit that focuses on mental health innovation and the development of an ecosystem for psychedelic-assisted therapies in Spain. Its official site presents it as a public-facing organization centered on psychedelic science, education, and access-related information for Spanish audiences. The organization appears to operate primarily in Spain, with content oriented to Spanish-language readers and European psychedelic policy developments. Fundación inawe is explicitly engaged in psychedelic medicine and access advocacy through public education, policy-aware commentary, and promotion of initiatives linked to regulated therapeutic use. On its site, it has highlighted the European citizen initiative PsychedeliCare Spain, the European Parliament group on psychedelic-assisted therapy, and coverage of EMA priority-status developments, suggesting a role as an education and mobilization hub rather than a direct clinical provider. Potential collaboration areas include researcher outreach, clinician education, funder engagement, and policy coordination around evidence-based access pathways and implementation in Spain and the EU.

The German Federal Ministry of Education and Research (BMBF) is the pioneering Western government funder of large-scale psychedelic clinical trials, having provided approximately €5 million to the EPIsoDE study — the first government-funded Phase 2 psilocybin trial for treatment-resistant major depression — conducted at the Central Institute for Mental Health in Mannheim and Charité Berlin. Germany subsequently became the first EU country to establish a psilocybin compassionate access program for treatment-resistant depression.

The Deutsche Gesellschaft für Psychedelische Forschung und Therapie e.V. is a German professional association based in Germany for physicians, psychologists, and other professionals working in psychedelic research and therapy. Its official site describes it as a specialist society that offers information exchange, supports standards and guidelines, and provides expert advice to professional and policy bodies. Membership is intended for professional practitioners rather than the general public. Its field role is centered on the scientific and clinical introduction of psychedelic-assisted therapies in Germany, with explicit attention to evidence, quality assurance, training, and public communication. The organization also says it supports patient- and family-oriented exchange, advises on certification and approval processes, and helps shape structural conditions for possible clinical use. Current site content highlights a 2026 case under Germany's compassionate-use program for psilocybin in depression, an online members' meeting, and planned contributions to the DGPPN congress.

HYSTELICA is a women-focused psychedelic research and education organization based in London, United Kingdom, with activity that appears to extend beyond the UK through its online content and academic collaborations. Its public-facing materials describe it as a non-profit, while UK company records identify HYSTELICA LTD as an active private limited company incorporated in 2022 with a London registered office. The organization says it serves women, people assigned female at birth, practitioners, researchers, and psychonauts seeking sex- and gender-aware psychedelic information. Its role in the field is centered on female biology, women’s mental health, and safer psychedelic use, with particular attention to menstruation, menopause, pregnancy, infertility, contraception, and other sex-specific considerations. Documented current projects include two recruiting studies run with King’s College London, on microdosing and menopausal symptoms and on female psychedelic use, plus a published paper on females in psychedelic research. It also offers educational programming and webinars, and has run a women’s retreat collaboration, which suggests potential partnership opportunities for researchers, clinicians, funders, policy groups, and patient communities interested in women-specific evidence, education, and harm-reduction-oriented access.

Heal Ukraine Trauma is a U.S.-based nonprofit initiative working with Ukrainian partners to address conflict-related trauma, especially for veterans and their families. Its programs combine service provision, training, public education, and the introduction of novel therapies in Ukraine. Its current public footprint is materially stronger than a generic trauma-relief description. The organization now describes Ukraine's first ketamine-assisted psychotherapy training program, a group-based care model for veterans, and repeated public-facing efforts tied to implementation and systems change.

Healing Advocacy Fund is a U.S.-based 501(c)(3) nonprofit focused on state-regulated psychedelic therapy access, with its clearest documented work in Oregon and Colorado and emerging references to New Mexico. It says it was formed after Oregon voters passed Measure 109 to help ensure the state’s psilocybin program was implemented as intended. Its public-facing materials describe it as supporting safe, affordable access to psychedelic healing for people who need it. The organization’s work centers on policy implementation, patient access, and public education around regulated psilocybin services. Documented activities include advocacy for Oregon program improvements, support for Colorado’s rollout under Proposition 122, educational resources for patients and clinicians, and an adverse-event reporting system in Oregon. Its field role appears to be a campaign and implementation-support organization that connects policy design, healthcare integration, and access expansion for regulated psychedelic therapy.

Canadian federal health regulator administering controlled access and oversight pathways relevant to psychedelic therapies.

The Health Research Board (HRB) is Ireland's primary statutory health research funding agency, which has awarded grants to Trinity College Dublin's Psychedelic Research Group to investigate psychedelics' immune effects in depression and the feasibility of psilocybin for cocaine-use disorder. The HRB also funds the KARMA-DEP(2) ketamine trial for treatment-resistant depression at St Patrick's University Hospital in Dublin, making it a key enabler of Ireland's emerging psychedelic medicine ecosystem.

Heroic Hearts Project is a veteran-serving nonprofit based in New York with program reach that spans the United States and multiple international retreat destinations. It primarily serves veterans and veteran spouses or families affected by military trauma and PTSD, and it provides psychedelic retreat programs, coaching, peer support, education, and other resources. The organization also states that it operates branches in Canada, the United Kingdom, and Australia, and it offers legal retreat options in Oregon as well as international retreats in countries where these medicines are legal. In the psychedelic medicine space, Heroic Hearts Project is an explicit access and advocacy organization focused on helping veterans access psychedelic-assisted care and on expanding pathways within health systems. Its website describes research collaborations, advocacy to improve access, and a policy arm called Healing Breakthrough, while also pointing to current initiatives such as guided psilocybin retreats, a veteran psychedelic field manual, and support for veteran spouses through The Hope Project. For researchers, clinicians, funders, and policy groups, the strongest collaboration fit appears to be veteran mental health outcomes research, implementation and referral pathways, retreat-to-care integration, and policy efforts that support safe, legal access for veterans and their families.

Heroic Hearts UK is a United Kingdom based nonprofit that connects military and emergency services veterans with psychedelic therapy retreat centres where those treatments are legal. Its public-facing materials describe it as facilitating healing for people struggling with mental trauma and linking them to progressive therapy retreats around the world, with a particular focus on veterans. The organization appears to serve a UK audience while working with retreat providers and support networks beyond the UK. In psychedelic medicine and access advocacy, Heroic Hearts UK is a veteran-focused patient access organization rather than a broad drug-policy group. Its current public activity includes referrals to discounted retreat options, research and event programming, and veteran and first responder education around psychedelic therapy and mental health. Public posts from the organization also indicate collaboration-oriented work on real-world evidence, occupational burnout, trauma-informed practice, and the need for wider access to psychedelic therapy for high-stress public service groups.

HoloMind is a Poland-based psychedelic education and therapy initiative centered on public information, training, and counseling related to therapeutic psychedelic use. Its site describes an educational portal, live and online trainings, and a counseling-oriented practice, and it also states that the group is creating a HoloMind Foundation and an Institute of Psychedelic Therapy. The organization appears to serve Polish audiences, with some materials and programs also framed for broader international outreach. In the psychedelic medicine and policy space, HoloMind positions itself around safer and more informed use, psychedelic integration, and improving access to knowledge about therapeutic pathways in Poland. Documented activities include education on the legal status of psychedelics in Poland, workshops on psychedelic integration, a supervision and intervention group, a 2025 therapy and integration conference, and content on veterans with depression and PTSD. It also references collaboration with other training and education partners, which suggests a field-building role for clinicians, researchers, funders, patient communities, and policy-oriented partners interested in education, implementation, and access.

ICEERS is a Spain-based nonprofit focused on the globalization of Indigenous plant medicines, with work spanning education, research, legal support, and community services. Its website describes three connected areas of work: mitigating harms and consequences, co-creating collaborative pathways, and international monitoring and research. The organization serves people navigating psychoactive plant use, health professionals, and Indigenous and community partners across multiple countries. In psychedelic and drug policy work, ICEERS combines harm reduction, public education, and policy advocacy rather than operating as a patient-access organization. Its current public-facing services include free integration and crisis support through El Faro, a drug-interaction information service, educational resources, and legal defense support for people facing prosecution related to traditional medicines. ICEERS also reports work with Indigenous partners and claims its efforts have informed court rulings and public policy, making it relevant to researchers, clinicians, funders, policy groups, and community stakeholders seeking evidence, safety, and rights-based collaboration.

IHPI, the Ibogaine Healthcare Policy Institute, is a U.S.-based 501(c)(3) nonprofit focused on policy infrastructure for regulated ibogaine care. Its stated audience includes healthcare decision-makers such as CMS, Medicaid leaders, commercial payers, regulators, and health system executives. The organization says it provides neutral, decision-grade resources on safety, payment, and implementation for ibogaine treatment. IHPI frames its role as building the legal and operational infrastructure needed for regulated ibogaine treatment in the United States, with an emphasis on veterans and people affected by PTSD and opioid use disorder. Its work includes regulatory pathways, safety and delivery standards, and payer system infrastructure such as reimbursement mechanics, coding roadmaps, budget impact logic, and coverage criteria. A published April 2026 explainer indicates it is actively interpreting federal psychedelic policy for downstream implementation, coverage, and delivery questions.

Hugvíkkandi, the Icelandic Psychedelic Society, is an Iceland-based membership organization founded in Reykjavík in September 2022. It describes itself as a platform for people interested in psychedelics to build community, strengthen advocacy, and learn about the topic, with an aim to support research, legal progress, and international collaboration. Its public-facing work centers on education, awareness-building, and policy or legal reform around psychedelics, with an explicit interest in strengthening ties to similar groups abroad. The organization has hosted or promoted educational programming in Iceland, including a MAPS educational program in November 2023 and a March 2024 workshop on psychedelic-assisted therapy, and it has published content discussing psilocybin use in cancer and end-of-life care.

The Independent Psychedelic Evidence Assessment Working Group (IPEA-WG) is a multidisciplinary working group focused on how evidence for psychedelic therapies should be evaluated. Its public materials indicate an international scope, with chairs and members from Europe, North America, and Brazil, and it appears to engage scientists, philosophers, clinicians, and regulatory experts rather than a single patient population. The group's core activity is to assess evidence-evaluation frameworks and develop expert recommendations relevant to regulators and policy design. IPEA-WG positions itself in the psychedelic medicine policy space by examining methodological and regulatory questions such as causality, trial design, conflicts of interest, and the limits of current evidence standards. Its site highlights talks, papers, and member expertise, and a public funder page says Norrsken Mind is supporting the group to develop rigorous, multidisciplinary standards for evaluating psychedelic evidence. Practical collaboration could include research consultation, regulatory science input, evidence-framework discussions, and policy briefings for clinicians, funders, and patient communities interested in access grounded in stronger evidence.

Pharmaceutical company responsible for the U.S. SUBLOCADE REMS program, including enrollment, certified healthcare setting controls, and controlled dispensing requirements.

Institut National de la Santé et de la Recherche Médicale (INSERM) is France's national public health and medical research agency, funding and conducting biomedical research across university-hospital institutes throughout the country. INSERM-affiliated researchers at the Paris Brain Institute (ICM) and Pitié-Salpêtrière Hospital have contributed to preclinical and clinical investigations of ketamine and psilocybin as rapid-acting antidepressants.

Instituto Mexicano del Seguro Social (IMSS) is Mexico's largest social security institute, operating the country's most extensive public hospital and clinic network serving over 70 million workers and their families. An IMSS-affiliated facility has participated in clinical research on ketamine for treating depressive symptoms in elderly patients with visual impairment.

Instituto de Salud Carlos III (ISCIII) is Spain's national public health research agency, managing the CIBERSAM network (Centro de Investigación Biomédica en Red de Salud Mental) which co-funds biomedical mental health research across Spanish universities and hospitals. Through CIBERSAM, ISCIII has co-funded preclinical and translational research on psilocybin as an antidepressant and supports researchers contributing to the European psychedelic therapy landscape.

Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE) is Mexico's federal social security institute for government employees, operating a nationwide network of hospitals and clinics serving millions of public-sector workers and their families. An ISSSTE-affiliated facility has participated in clinical research examining ketamine's effect on depressive symptoms in elderly patients with visual impairment.

The International Alliance of MDMA Practitioners, also known as the MDMA Alliance, is a nonprofit professional organization for practitioners who offer MDMA-assisted therapy in legal settings. Its public materials describe a global network of experienced clinicians and researchers who provide community, resources, training, continuing education, and referral connections for members. The organization says it serves licensed mental health and healthcare practitioners, including international members, who have MDMA-assisted therapy or related psychedelic therapy experience. The MDMA Alliance presents itself as a field-building group focused on advancing MDMA-assisted therapy through education, advocacy, community, and best-practice development. It says it advocates for the appropriate use of MDMA-assisted therapy as the field evolves, and that it will develop clinical and ethical standards for the profession. Public-facing materials also describe member activities such as monthly meetings, in-person retreats, an online forum, a resource hub, and a referral list of therapists and supervisors.

IDPAT is an Irish organization of doctors, psychotherapists, researchers, and other healthcare workers advocating for psychedelic-assisted therapy in Ireland. Its patient relevance is real, but it is mediated through clinician advocacy, health-system reform, and public reimbursement arguments. The record should therefore be recast as a multi-role stakeholder rather than a straightforward patient organization. Its public language centers on making psychedelic-assisted therapy publicly available and reimbursed, which is highly relevant to access policy and implementation planning.

Istituto Superiore di Sanità (ISS) is Italy's National Institute of Health, the country's principal technical and scientific public body for biomedical research, public health surveillance, and regulatory advisory functions. The institute has participated in pharmacological research on designer psychoactive substances including methylone, an MDMA analogue, contributing to Italy's evidence base for novel psychoactive substance regulation.

SIMEPSI, the Italian Society for Psychedelic Medicine, is a nonprofit scientific society based in Italy and focused on psychedelic medicine. Its official materials describe it as a multidisciplinary community of doctors, therapists, researchers, and humanists working to advance research and informed discussion on psychedelic compounds and their therapeutic potential. It appears to operate nationally, with a primary focus on the Italian regulatory and clinical context. SIMEPSI presents itself as a field-building organization rather than a patient service provider. Its stated activities include promoting clinical and basic research, sharing knowledge among experts, supporting training and professional development, and collaborating with institutions on regulation and safe access to psychedelic treatments. It also frames part of its role around public education, risk awareness, and discussion of the social and cultural implications of psychedelic practices.

Pharmaceutical sponsor operating SPRAVATO REMS restricted-distribution controls for supervised administration, site certification, and patient enrollment in the US market.

Biopharmaceutical company that administers the U.S. XYWAV and XYREM REMS restricted distribution program, including certification, dispensing controls, and program reporting requirements.

Kykeon, also presented as the Greek Psychedelic Society, is a Greece-based nonprofit collective focused on education, advocacy, policy, and community building around psychedelics. Its public materials describe work to mobilize a national movement, reduce stigma, and support safe, equitable, and inclusive access to psychedelic-assisted therapies and other healing modalities in Greece. The organization says it serves the Greek public, people interested in psychedelics, and a broader national dialogue on drug policy and altered states of consciousness. Its public-facing role centers on policy reform and public education rather than direct clinical service delivery. The group says it disseminates scientific information, supports reform of the Greek legal framework around psychedelics, hosts dialogues and integration circles, maintains a directory of therapists trained in psychedelic-related modalities, and curates harm-reduction information. Current site content also shows ongoing publishing and issue framing on topics such as psilocybin, harm reduction, medical uses, and international policy developments, which suggests a field role in public awareness, community convening, and reform-oriented advocacy.

The Luca Coscioni Association is an Italian civil society organization based in Rome that says it defends the right to science, care, and freedom of choice. Its public work spans end-of-life rights, disability, civil liberties, and science-and-health policy, using appeals, legal actions, and public service initiatives. The group also describes itself as preparing technical documents to support legislative, judicial, and policy proposals. In drug policy, the association is an active Italian and European reform advocate rather than a patient group. It has backed a civil-society drug policy plan focused on legal regulation starting with cannabis, harm reduction, proportional penalties, and stronger access to treatment, and it has also called for regulated clinical access to psychedelic therapies based on scientific evidence. Its role appears to bridge researchers, clinicians, advocates, and affected communities, especially around medical cannabis, harm reduction, and evidence-based access reform.

Long Alliantie Nederland is a Dutch patient alliance representing people affected by lung disease, including severe COPD. Its psychedelic relevance is specific rather than generalized, because it is an active patient partner in the EU-funded PsyPal trial on psilocybin-assisted therapy in palliative care. That role makes the stakeholder more useful than a passive consortium mention. The alliance has publicly promoted the PsyPal launch, later recruitment opportunities, and the first patient selection, giving Blossom a clear Netherlands-based example of disease-community involvement in psychedelic implementation research.

MAPS, the Multidisciplinary Association for Psychedelic Studies, is a U.S.-based 501(c)(3) nonprofit research and educational organization founded in 1986. It works nationally and with a broader global audience to develop medical, legal, and cultural contexts for the careful use of psychedelics and marijuana. Its core activities include research, education, advocacy, and convening the field through large public events. In psychedelic medicine and policy, MAPS positions itself as an advocate for legal access, drug policy reform, harm reduction, and health equity. Its Policy & Advocacy work includes legislative advocacy, community organizing, and impact litigation, and it has also launched work on access for system-impacted people and broader health equity in the legal psychedelic ecosystem. Current documented initiatives include the Psychedelic Science conference series, the Health Equity Program, The Zendo Project, and Ask MAPS, which handles public inquiries about therapy, research, and policy reform.

MAPS Europe B.V. is an Amsterdam-based Dutch subsidiary of the Multidisciplinary Association for Psychedelic Studies that operates as a clinical trial sponsor for MDMA-assisted psychotherapy research in Europe. Its public-facing work centers on advancing prescription pathways for MDMA in the treatment of post-traumatic stress disorder and coordinating regulated clinical research across multiple European sites. Its role in the field is primarily research and access-oriented rather than broad drug policy advocacy. Public protocol materials describe a multicenter European open-label Phase 2 study for PTSD, with therapy-team training and a planned Phase 3 lead-in, suggesting a focus on clinical evidence generation, therapist preparation, and regulatory submission support. For researchers, clinicians, funders, and policy groups, the most relevant collaboration opportunities appear to be trial participation, clinical training, implementation planning, and evidence-to-regulation work for MDMA-assisted psychotherapy.

MAPS Italia is a nonprofit organization founded in 2024 and based in Italy. Its public-facing mission is to promote informed dialogue about the therapeutic use of psychedelic substances, with an emphasis on evidence-based information, education, and a scientific perspective. The organization says it serves people interested in psychedelic medicine, as well as health professionals and the broader Italian public. MAPS Italia positions itself as an educational and advocacy-oriented stakeholder in psychedelic medicine rather than a clinical provider. Its website describes work on public information, events, publications, and professional training, including an international MDMA-assisted therapy training planned for Italy in 2026 and a 2024 conference on the clinical use of psychedelic substances. It also references broader European policy interest, including the 2025 Psychedelicare.eu European Citizens' Initiative, suggesting a role in awareness-building and policy-facing dialogue around regulated therapeutic access.

UK medicines regulator overseeing trial authorizations, pharmacovigilance, and market-authorization pathways.

Mind Medicine Australia is a national nonprofit that has played a defining role in Australia's regulated psychedelic-access environment. Its public work spans rescheduling advocacy, implementation support, clinician training, patient support funding, and ongoing efforts to broaden access pathways. Although it is broader than a pure patient group, it is too important to leave out of Blossom's access map. The organization now reports active involvement in regulatory follow-through, rollout improvements, patient support, and collaboration with End Wise on palliative-care expansion.

The National Association for Psychedelic Research in Serbia is a Serbia-based nonprofit association focused on psychedelic research, education, advocacy, and community engagement. Its public materials say it serves professionals and the general public through educational programs, seminars, workshops, conferences, and meetings that discuss psychedelics and mental health. The organization also presents itself as a platform for experts, psychiatrists, psychotherapists, and interested individuals. Its public-facing role is explicitly tied to psychedelic medicine and policy change, with advocacy for strictly controlled therapeutic access and support for scientific research on psychedelics. The site highlights content on MDMA-assisted psychotherapy, psilocybin-assisted psychotherapy, and ayahuasca research, and notes that psychedelic use is illegal in Serbia under the Law on Psychoactive Controlled Substances. Public materials also suggest collaboration interests around early access programs and international non-profit networking in the psychedelic field.

The National Cancer Institute (NCI) is the principal US federal agency for cancer research and training, one of 27 institutes within the National Institutes of Health, with an annual budget exceeding $7 billion. In the psychedelic field, NCI has supported trials exploring psilocybin-assisted therapy for cancer-related demoralization and chronic pain in survivors, as well as ketamine infusion to prevent depression in patients undergoing treatment for pancreatic and head-and-neck cancers.

NIH center that accelerates the translation of biomedical discoveries into health solutions. NCATS' Clinical and Translational Science Awards (CTSA) program funds the infrastructure at academic medical centers that supports emerging research including psychedelic-assisted therapy trials.

U.S. federal institute focused on complementary/integrative research and evidence programs including psychedelic-adjacent contexts.

The National Center for PTSD (NC-PTSD) is a US Department of Veterans Affairs centre of excellence for research, education, and training on post-traumatic stress disorder, operating across seven VA medical centre sites with a focus on evidence-based assessment and treatment. The Centre has supported mechanistic ketamine research in military and veteran populations, including an investigation of AMPA receptor blockade on ketamine’s anti-suicidal effects relevant to veteran mental health crises.

The National Center for Research Resources (NCRR) was a National Institutes of Health centre that funded biomedical research infrastructure, clinical and translational science programmes, and shared research resources until its dissolution in 2011, when its programmes were reorganised primarily into the new National Center for Advancing Translational Sciences (NCATS). NCRR infrastructure and clinical research awards supported early NIH-funded investigations into glutamate-modulating medications for major depressive disorder that laid the mechanistic groundwork for understanding ketamine’s rapid antidepressant effects.

Ireland’s national HTA and pharmacoeconomics body that conducts rapid review and full HTA for reimbursement decisions, including esketamine references.

The National Council of Scientific and Technical Research (CONICET; Consejo Nacional de Investigaciones Científicas y Técnicas) is Argentina’s principal government agency for promoting science and technology, funding over 11,000 researchers and 10,000 doctoral students across a nationwide network of research institutes and centres. CONICET supported the NATMICRO study, a naturalistic observational investigation of the psychological and cognitive effects of self-administered psilocybin microdosing conducted in Argentina.

UK public health research funder and implementation infrastructure supporting NHS-oriented evidence generation.

UK HTA body issuing evidence and cost-effectiveness recommendations that influence medicine access.

U.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) is a US National Institutes of Health institute dedicated to research on alcohol use disorder and its public health impacts, supporting approximately $500 million in research annually. NIAAA has funded studies exploring both ketamine administration for acute alcohol use disorder in the emergency department and psilocybin-assisted therapy to understand the neurobehavioral mechanisms underlying alcohol use disorder treatment.

U.S. federal institute setting addiction-research priorities and portfolios, including psychedelic-related investigations.

U.S. federal biomedical research agency shaping institute-level priority and research funding architecture.

The National Network of Depression Centers is a U.S.-based nonprofit consortium of academic medical centers and mental health programs focused on depression, bipolar disorder, and related mood disorders. It operates nationally across member sites in the United States and is centered in Ann Arbor, Michigan. Its core activities include collaborative research, clinical education, outreach, and network-based improvement of evidence-based care. In the psychedelic-adjacent space, NNDC appears primarily as a mood-disorders research and clinical collaboration network rather than a dedicated psychedelic policy group. Its ketamine task group was created to share information and experience as ketamine and esketamine clinics expanded across the network, and NNDC has also reported on the BIO-K biomarker study of ketamine for major depression. This makes it relevant to researchers, clinicians, and funders working on interventional psychiatry, treatment-resistant depression, and evidence-building around regulated access pathways.

New Mexico state health authority responsible for implementation and oversight of the Medical Psilocybin Act program.

Oregon state health authority administering Oregon Psilocybin Services licensing and implementation oversight.

State-level Oregon pharmacy and therapeutics decision body supporting evidence-driven formulary and utilization policy.

The Oregon Psilocybin Advisory Board is a state advisory body within the Oregon Health Authority that operates in Oregon. It was established under Oregon law to make recommendations on scientific evidence, safety and efficacy, and the requirements, specifications, and guidelines for psilocybin services in the state. Its work is oriented toward public meetings, advisory recommendations, and related subcommittee and workgroup processes. In Oregon's regulated psilocybin system, the board functions as an implementation and policy guidance group rather than a direct service provider. Source materials show it has produced evidence reviews and has supported ongoing advisory and workgroup activity tied to psilocybin service rules, product issues, and public comment opportunities. Potential collaboration areas include regulatory implementation, evidence review, clinical and facilitator standards, public health safeguards, and access-oriented policy feedback from researchers, clinicians, funders, and patient or community stakeholders.

Australia’s HTA and reimbursement advisory body for PBS listing decisions, including esketamine (Spravato) assessment materials.

Polish Psychedelic Society, or Polskie Towarzystwo Psychodeliczne, is a Polish initiative that emerged in 2019 within the Polish Drug Policy Network. It operates in Poland and appears to serve a national audience of researchers, clinicians, activists, and people interested in psychedelic science and policy. Its core activities are to popularize evidence-based knowledge about psychedelics, support scientific research, and create an interdisciplinary forum for discussion. The organization combines public education with policy advocacy around psychedelic regulation, including decriminalization, legal status reform, harm reduction education, and legal support for people charged with possession for personal use. It also describes itself as working to improve access to medical cannabis in Poland, which is adjacent to broader controlled-substance reform. Documented collaboration areas include research translation, clinician education, policy briefing, patient-facing education, and coalition work on rational drug regulation.

Psilocybin Access Rights is a volunteer-led advocacy campaign based in the United Kingdom that calls on the UK government to reschedule psilocybin so it can be made accessible for patients and researchers. The group frames its work around public access, medical research, and safer legal pathways for psilocybin use, rather than commercial service delivery. Its public role is in psychedelic medicine policy and patient access advocacy, with a focus on mental health and related conditions such as depression, addiction, cluster headaches, and end-of-life distress. Documented current initiatives include Project Croydon, later renamed Project Hull, plus petitioning MPs, public awareness activities, and campaign outreach to support rescheduling and legal medical access.

PsychedeliCare is a Europe-wide European Citizens’ Initiative centered on psychedelic-assisted therapy policy in the European Union. It operates across EU member states and has also described participation from partners and citizens in non-EU countries, with volunteers and supporters organizing outreach in multiple countries. Its core activities include signature gathering, public campaigning, volunteer mobilization, and citizen engagement around EU-level mental health policy. The initiative’s policy agenda focuses on making psychedelic-assisted therapies available and affordable in Europe through standardized therapeutic guidelines, increased EU research funding, and a common EU stance on international legal classification. It frames its work around mental health access, evidence-based treatment, and cross-border policy alignment, and it has used an activist pack, newsletter sign-ups, and partner outreach as practical campaign tools. For researchers, clinicians, funders, and policy groups, the main collaboration opportunities appear to be research, training, standards development, and implementation-policy dialogue.

PAREA is a European nonprofit alliance working to make psychedelic-assisted care safe, evidence-based, accessible, and reimbursed across European health systems. It brings together patient groups, professional bodies, umbrella organizations, foundations, and other stakeholders in a coordinated regional policy platform. This is one of the highest-value adjacent additions for Blossom's advocacy matrix because it operates at the EU policy layer rather than at a single-country patient-group layer. Its current work includes the MEP Action Group on Psychedelics in Healthcare, formal EU consultation input, cross-country convening, and reimbursement-oriented policy development.

Psychedelic Coalition for Health is a U.S.-based psychedelic medicine education, training, and advocacy project led by clinicians Lauren Taus and Nicholas Brüss. Its public-facing work is centered on licensed health professionals, with Los Angeles-based in-person training and virtual programming that can reach a broader audience. The organization presents itself as serving clinicians and people interested in psychedelic health and well-being. PCH offers psychedelic-assisted therapy and integration training, a virtual psychedelic medicine symposium, and continuing education programming. Its site says the group advocates for psychedelic health and happiness, supports science over stigma, and includes equity-oriented scholarship offerings for training participants. The coalition also frames its work around responsible implementation of psychedelic medicine and education on current research and clinical practice.

Psychedelic Lived Experiences is a patient-led initiative bridging clinical science and lived experience in psychedelic care. It convenes patients, trial participants, therapists, researchers, advocates, and policymakers through summit programming, community, support resources, and education so firsthand expertise can inform research, practice, and policy decisions. Its advocacy work centers patient and trial participant voices in research, treatment design, therapist education, policy discussions, and standards of care. The initiative has operated internationally since 2019 through conference and policy presentations, publications, media, summit programming, and professional workshops focused on patient safety, ethics, access, and quality infrastructure.

Psychedelic Medicine Coalition is a Washington, D.C.-based nonprofit advocacy organization focused on psychedelic medicine policy in the United States. Its official materials describe it as a nonpartisan 501(c)(3) that works on federal and state advocacy, with a stated emphasis on research, policy, and responsible implementation of psychedelic medicine in health care. It appears to operate nationally, while also engaging district-level and state/local policy processes. The organization frames its role as educating lawmakers, hosting briefings and meetings, and working on legislation, testimony, appropriations, and policy implementation. Documented current work includes a federal summit on psychedelic medicine, a legislation tracker in partnership with Psychedelic Vote, and advocacy around the Innovative Therapies Centers of Excellence Act for veterans. Its likely field role is as a policy convening and lobbying bridge between researchers, clinicians, advocates, and government stakeholders, with potential collaboration points in evidence briefing, legislative strategy, implementation planning, and access-oriented coalition building.

Psychedelic Medicine PAC is a U.S.-focused political action organization that says it works to elect leaders who support science-based psychedelic medicine policy. Its website frames the group as advocating for candidates who support psychedelic medicine access and rescheduling at both state and federal levels. The organization appears to operate nationally within the United States rather than serving a single state or locality. The PAC presents itself as a political advocacy group tied to psychedelic medicine reform, with emphasis on rescheduling, research, access to safe treatments, and broader mental health policy change. Its public messaging also references veterans, overdose deaths, and trauma as reasons for action, suggesting a policy role that connects psychedelic reform with public health and patient access. Documented activity on the site includes weekly news and updates, donation-based political support, and support for state and federal rescheduling movements.

PsyPAN is a nonprofit participant advocacy network for people who have taken part in psychedelic clinical trials or received treatment at legal psychedelic therapy centers. It focuses on participant wellbeing, post-treatment support, feedback loops, and sector-wide best practice grounded in lived experience. This is a high-value addition because it covers a stakeholder type that is still under-mapped: former and current treatment participants as an organized voice. PsyPAN is especially relevant wherever clinical trials, legal treatment centers, or retreat-linked pathways need independent participant insight, safeguarding input, and aftercare design.

Psychedelic Research in Science & Medicine (PRISM) is an Australian nonprofit research charity based in Melbourne, with activity and collaborators across Australia and internationally. It was established in 2011 to initiate, coordinate, and support formal research into medicinal psychedelics and related technologies. PRISM says it serves researchers, clinicians, and the wider psychedelic science community through scientific expertise, education, and consultation. PRISM’s public role is centered on evidence-based psychedelic science, knowledge translation, and policy-facing advocacy rather than direct patient services. Its website describes a research network that connects academics, clinicians, and students to coordinate study proposals, collaborations, funding opportunities, and peer-to-peer education. Documented current initiatives include a Psychedelic Research Network and support for Australian clinical research, including work related to psilocybin, MDMA, and virtual reality tools for preparation and integration.

Psychedelic Society Belgium is a Belgium-based nonprofit community organization founded in 2020 and centered in Meise, Belgium. It operates nationally within Belgium and appears to focus on public education, community building, and discussion around psychedelics and psychedelic-assisted mental health care. Its website describes it as a community dedicated to advancing psychedelics and invites participation through events, membership, volunteering, and donations. Its stated mission is to advocate for psychedelic-assisted mental health care and to create a legal framework for the safe and therapeutic use of psychedelics in Belgium. The organization also says it aims to inform the public objectively, support Belgian research, and provide harm-reduction information on legality, safety, and set and setting. Its current visible activity includes monthly meetups, a webinar series, journal clubs, lectures, and a 2026 symposium in Brussels focused on integrity, ethics, and harm reduction in psychedelic therapy.

PsychedelicsEUROPE is a Brussels-based advocacy platform focused on EU regulation and novel mental health treatments. Its stated audience includes policymakers, regulators, researchers, and businesses, and it says it works to foster collaboration, share best practices, and support implementation of a new regulatory framework across Europe. The organization lists a Brussels address and frames its work at the European Union level, with attention to member state policy contexts. The group presents itself as a policy and access intermediary for psychedelic and other innovative mental health therapies, emphasizing reimbursement, regulatory pathways, and health-system integration. It says it engages with EU institutions, builds strategic coalitions, and supports post-conflict mental health recovery, including PTSD-related work connected to Ukraine. Documented activities on its site include policy roundtables in Brussels and Ukraine, a high-level conference in Prague, and field visits and meetings with government officials and health professionals in Ukraine.

Psychédelos is a Swiss patient association for people who have legally received psychedelic-assisted therapy under Switzerland's exceptional-access framework. It centers lived experience, peer support, public explanation of Swiss access pathways, and practical patient-protection tools. The organization is especially valuable because it brings a patient voice into one of the few durable legal access environments in Europe. Its current public model includes membership for treated patients, speaking circles in Geneva and Lausanne, and an ombudsman function for patients.

Canada�s national public health agency responsible for surveillance, risk assessment, and public-health guidance.

Reconnect Foundation is a Swiss charitable organization that operates from Switzerland and supports work at the intersection of consciousness research, healthcare accessibility, and ecosystem conservation. Its public materials describe an emphasis on open science, support for academic research, and collaboration with Indigenous Peoples and local communities. It also says the foundation was established by the founders of Reconnect Labs, a Swiss biotech company based at the University of Zurich. In psychedelic-adjacent work, Reconnect Foundation says it supports consciousness research using psychedelics and other consciousness-altering methods, along with mindfulness and ethnobotanical research into ancestral practices. It also runs a benefit-sharing and ecosystem restoration effort focused on Indigenous rights, biocultural conservation, and consultation with Indigenous leaders and partner NGOs in the Amazon region. Documented collaborators named on its site include the Indigenous Medicine Conservation Fund, ICEERS, and El Puente.

Release is a UK drugs law and legal reform organization based in London and operating nationally across England and Wales through advice, legal support, outreach, and policy work. Its public-facing services include a national helpline, legal advice, drug advocacy, and community legal welfare outreach delivered in drug treatment centers, homelessness projects, and sexual health clinics across 21 locations. It says its core audience includes people with a history of drug use, people affected by drug laws, and professionals seeking advice on drug law and harm reduction. Release’s advocacy role is centered on evidence-based drug policy, public health, human rights, and decriminalization, with published research on racial disparities in drug enforcement and comparative decriminalization models. Its current public work includes the “Gear Has Changed” public health campaign on drug supply contamination and ongoing responses to government and international consultations on drug laws and enforcement. It is adjacent to psychedelic policy rather than psychedelic-specific, but its drug law, harm reduction, and controlled-substance expertise may be relevant to researchers, clinicians, funders, policy groups, and patient communities working on regulated access and reform.

Regional psychiatric college issuing clinical memoranda and implementation guidance on psychedelic-assisted therapy, including MDMA and psilocybin use in regulated psychiatric contexts.

Salt City Psychedelic Therapy and Research (SCPTR) is a Utah-based nonprofit serving the Intermountain West, with a U.S. headquarters and regional focus. It was founded by the late Dr. Parth Gandhi and is described as advancing psychedelic-assisted therapy through education, research, and advocacy. SCPTR’s field role is centered on public education, practitioner and researcher support, and regional policy reform around psychedelic-assisted therapy. Publicly documented activity includes organizing the annual Intermountain Psychedelic Symposium, which has been described as a venue for learning, networking, harm reduction, and local fundraising for clinical trials in Utah.

SPACE is a Portuguese scientific association founded in May 2021 by psychiatry physicians. It is based in Portugal and appears to operate primarily as a national scientific and educational association focused on psychedelic medicine. Its public-facing work centers on studying, disseminating, and building knowledge about the therapeutic properties and uses of psychedelic substances, especially in clinical mental health settings. SPACE frames part of its role as supporting regulation and clinical guidance for psychedelic use, while also promoting ethical practice, collaboration with scientific and governmental bodies, and outreach to health professionals, patient associations, and the general public. The organization also publishes educational resources and scientific content on psychedelics and related topics, including ketamine, psilocybin, LSD, MDMA, ayahuasca, and ibogaine. Its current web presence suggests active educational programming and field-building rather than direct service delivery or formal political campaigning.

Scotland’s public HTA body issuing medicine acceptance guidance, including esketamine (Spravato) advice.

La Société psychédélique française est une association basée en France qui se présente comme un espace de médiation culturelle et scientifique autour du psychédélisme. Elle vise surtout un public de chercheurs, d’étudiants et de personnes intéressées par les questions scientifiques, culturelles et de réduction des risques liées aux substances psychédéliques. Son activité est principalement nationale, avec des antennes et événements dans plusieurs villes françaises. Dans le champ des psychédéliques, son rôle est centré sur l’éducation publique, la mise en réseau de personnes du milieu académique et de la santé, et l’organisation d’événements de discussion ou d’étude. L’association a notamment organisé une première journée d’étude universitaire sur les études psychédéliques en France et propose des cercles d’intégration et des ressources de réduction des risques. Elle peut être pertinente pour des collaborations autour de la recherche, de la médiation scientifique, de la formation, et du dialogue entre chercheurs, cliniciens, et communautés d’usagers.

SEMPsi, or the Sociedad Española de Medicina Psicodélica, is a Spanish nonprofit society made up of clinical professionals and mental health researchers. It operates primarily in Spain and appears to serve clinicians, researchers, and other health professionals interested in psychedelic medicine. The group describes its work as promoting therapeutic use and research on psychedelics in an ethical, culturally respectful, evidence-based context. SEMPsi's role is mainly public education, professional formation, and field-building rather than direct patient service delivery. Its manifesto says it produces scientific outreach, training, ethical codes, treatment protocols, and good-practice guidance, and it also aims to advise public and private institutions on clinical use and future legal implementation. Documented current activity includes journal clubs, a university course on psychedelic-assisted psychotherapies, and a parliamentary event in Spain on psychedelic-assisted therapies, as well as coordination with the citizen initiative PsychedeliCare.

Students for Sensible Drug Policy is a global youth-led network focused on drug policy reform, with chapters and affiliates in the United States and other countries. It organizes students, young professionals, and emerging advocates through campus chapters, community chapters, and ambassador activities. Its core work includes policy advocacy, public education, and local organizing around drug laws and campus policies. SSDP is explicitly engaged in psychedelic policy reform as part of its broader drug policy agenda. Current documented efforts include its Psychedelic Policy Reform work, the Psychedelic Pipeline for career development and mentorship, and sponsorship of the North Carolina Psychedelic Policy Coalition. The group also works on blocking restrictions on psychedelic research chemicals and on broader reform areas such as harm reduction, decriminalization, and student-facing drug education.

U.S. national public health agency for behavioral health policy and surveillance, including hallucinogen and ketamine epidemiology in national datasets.

Swiss federal authority issuing exceptional licences for otherwise prohibited narcotics, including controlled pathways relevant to psychedelic substances under medical/scientific exceptions.

The Swiss Medical Association for Psychedelic Therapy (SÄPT) is a Switzerland-based professional medical society founded in 1986, with a German-speaking, interdisciplinary membership that includes psychiatry, psychotherapy, neurology, palliative care, and general medicine. It operates nationally in Switzerland and reports roughly 260 members. Its core activities include improving clinical quality in psychedelic-assisted therapy, supporting professional exchange, and providing theoretical and practical training. SÄPT plays a field-building role in Switzerland’s psychedelic medicine ecosystem by promoting research, developing ethical and treatment standards, and supporting practitioners working under Swiss exceptional authorizations. The organization also engages in policy and health-system advocacy on behalf of its members and participates in the IG PAT network, which issues treatment recommendations for psychedelic-assisted therapy. Current documented initiatives include an education calendar, an academy/training offer, research pages, institutional working groups, and an ombud/service function for people seeking information about psychedelic therapy.

The Swiss Medical Society for Psycholytic Therapy, now presented on its site as SÄPT, is a Switzerland-based interdisciplinary medical society founded in 1986. It primarily serves German-speaking clinicians and related therapeutic professionals, including psychiatry, psychotherapy, neurology, palliative care, general medicine, psychology, and other therapeutic fields. Its core activities include professional exchange, training, and supporting medically supervised psychedelic-assisted therapy. SÄPT positions itself as a field-building organization for psychedelic-assisted therapy in Switzerland, with a focus on research support, quality standards, and professional education. Its website states that members have supported studies involving MDMA-assisted psychotherapy and LSD-assisted psychotherapy, and it currently lists ongoing or recent study and training announcements, including LSD studies for life-limiting illness, cluster headache, alcohol dependence, and older adults, plus an institutional PAT working group and treatment recommendations through IG PAT. It also provides patient-facing information on where psychedelic-assisted therapy may be available and on support options for difficult psychedelic experiences, which makes it a practical access and referral-adjacent stakeholder rather than a broad public advocacy group. Historically, SÄPT reports that five therapists received Swiss federal exception permits from 1988 to 1993 to conduct psychedelic-assisted therapy with MDMA and LSD in private practice, treating about 170 patients. Today it appears to operate mainly as a professional society that advances psycholytic therapy through education, research collaboration, ethical standards, and guidance for clinicians working within Switzerland’s restricted medical-use framework. Potential collaboration areas include clinical research, training, treatment standards, institutional implementation, and patient information pathways for researchers, clinicians, funders, policy groups, and patient communities.

U.S. shared-system REMS program for transmucosal immediate-release fentanyl products, maintaining restricted prescriber, pharmacy, and patient enrollment controls.

Texas state health agency overseeing policy functions and implementation of psychedelic-adjacent public initiatives such as ibogaine programs.

TheraPsil is a Canadian nonprofit focused on legal access to psychedelic-assisted therapy for people in medical need. Its current public work spans patient navigation, prescriber and therapist training, referrals, and sustained advocacy around federal access pathways. The organization remains one of the clearest Canadian patient-access stakeholders because it links policy work to concrete care pathways. Current materials show active work on Project Solace, ongoing clinician upskilling, and new Manitoba progress around MDMA-assisted therapy.

Australian national regulator for scheduling, prescribing pathways, and safety oversight including MDMA/psilocybin psychiatry contexts.

Transform Drug Policy Foundation is a UK-based independent charity that works nationally and internationally on drug policy reform. Its main audience includes policymakers, the public, governments, and practitioners, and its core work is public education, policy analysis, and promoting legal regulation models for currently illegal drugs. In psychedelic policy, Transform is clearly active and has published guidance on how to regulate psychedelics, with a focus on non-medical adult use and broader legal frameworks. Its work also emphasizes equity, Indigenous rights, corporate capture mitigation, and international treaty questions, making it relevant to policy groups, researchers, funders, and community stakeholders interested in regulated access and drug law reform.

U.S. federal veterans health authority with explicit psychedelic-adjacent clinical research and care-implementation activity through VA research and care networks.

US federal regulator for drug development and safety oversight, including psychedelic clinical-investigation pathways.

UK national public health agency responsible for surveillance and population-risk evidence, including substance-harm monitoring referenced in ketamine policy review.

The Ukrainian Psychedelic Research Association is a non-profit organization based in Ukraine that promotes legal psychedelic-assisted therapy and scientific research on psychedelics. Its public materials describe a national focus on Ukraine, with outreach framed around doctors, the military, and society more broadly. The organization says it works within current law and emphasizes ethics, scientific rigor, and evidence-based practice. UPRA presents its field role as advancing clinical use and research for people affected by trauma, especially patients with post-traumatic stress disorder who have not benefited from conventional therapy. It also says it seeks to help veterans, displaced people, and bereaved communities, and to support legislative regulation, expanded access programs, professional training, and patient and caregiver support. Publicly visible current work includes regulatory dialogue, education, professional development, and collaboration on launching the first clinical trials of MDMA and other psychedelics in Ukraine.

U.S. Veterans Affairs research authority overseeing national veteran-focused clinical research programs including psychedelic-adjacent initiatives.

VMHLC is a veteran-member nonprofit coalition built around ending veteran suicide through expanded access to psychedelic-assisted therapies and other emerging treatments. Its center of gravity is coalition advocacy, policy alignment, and movement-building across veteran-serving organizations. That profile is valuable to Blossom, but it fits better as a policy campaign coalition than as a patient advocacy organization. The strongest public evidence points to federal and state advocacy, coalition mobilization, and legislative support rather than direct patient support infrastructure.

VETS is a veteran-focused nonprofit working to expand access to psychedelic-assisted therapies for service members and veterans. Its model combines direct support, public education, veteran storytelling, and increasingly visible state-by-state policy engagement. In 2026, VETS publicly reported tracking psychedelic policy in dozens of states and being directly engaged in most of them. That makes it one of the strongest current U.S. stakeholders for veteran-centered access strategy, legislative intelligence, and implementation advocacy.

Washington state health authority overseeing health programs and hosting the state psilocybin task force process under public-health governance structures.

Washington State HTA program conducting evidence review that informs state coverage and utilization policy.

U.S. REMS program for isotretinoin products that enforces pregnancy-prevention controls through prescriber, pharmacy, and patient workflow requirements.